Dr. Hina Khan is an Assistant Professor of Medicine in the Hematology and Oncology division. She is a Thoracic Oncologist at the Cancer Center at Brown University-Lifespan Cancer Institute in Providence, Rhode Island. With her clinical and translational expertise, Dr. Khan has led several University, pharmaceutical and NIH-funded projects as a principal investigator. Her ongoing translational work focuses on enhancing responses to immune checkpoint inhibitors in preclinical and lung cancer organoid models; and build on the role of Chi3L1 in response to immune checkpoint therapy in metastatic lung cancer. She is the site investigator for the CCC-19 (consortium for COVID-19 and cancer) and TERAVOLT (Thoracic cancers international COVID-19 collaboration registry) registries, and heavily invested in studying outcomes of COVID-19 in lung cancer patients. Dr. Khan also has a truly informed commitment to increasing diversity in clinical trials, given her background as a South Asian immigrant and an academic lung cancer expert. In Rhode Island, she has studied the burden of Radon exposure and its genomic imprints on lung cancer. She is identifying areas with significant exposure and studying ways to improve patient outcomes. She is currently, also leading a comprehensive program of public education and nodule management to increase Lung Cancer Screening in the Underserved Populations of Rhode Island.